Literature DB >> 28718416

The Untold Story of Granzymes in Oncoimmunology: Novel Opportunities with Old Acquaintances.

Maykel Arias1, Luis Martínez-Lostao2, Llipsy Santiago3, Angel Ferrandez4, David J Granville5, Julián Pardo6.   

Abstract

For more than 20 years perforin and granzymes (GZMs) have been recognized as key cell death executors of cytotoxic T (Tc) and natural killer (NK) cells during cancer immunosurveillance. In immune surveillance, perforin and GZMB, the most potent cytotoxic molecules, act mainly as antitumoral and anti-infectious factors. However, when expressed by immune regulatory cells they may contribute to immune evasion of specific cancer types. By contrast, the other major granzyme, GZMA, seems not to play a major role in Tc/NK cell-mediated cytotoxicity, but acts as a proinflammatory cytokine that might contribute to cancer development. Members of the GZM family also regulate other biological processes unrelated to cell death, such as angiogenesis, vascular integrity, extracellular matrix remodeling, and barrier function, all of which contribute to cancer initiation and progression. Thus, a new paradigm is emerging in the field of oncoimmunology. Can GZMs act as protumoral factors under some circumstances? We review the diverse roles of GZMs in cancer progression, and new therapeutic opportunities emerging from targeting these protumoral roles. Crown
Copyright © 2017. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  cancer progression; extracellular matrix; granzymes; inflammation

Mesh:

Substances:

Year:  2017        PMID: 28718416     DOI: 10.1016/j.trecan.2017.04.001

Source DB:  PubMed          Journal:  Trends Cancer        ISSN: 2405-8025


  28 in total

1.  Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial.

Authors:  Sarah B Goldberg; Kurt A Schalper; Scott N Gettinger; Amit Mahajan; Roy S Herbst; Anne C Chiang; Rogerio Lilenbaum; Frederick H Wilson; Sacit Bulent Omay; James B Yu; Lucia Jilaveanu; Thuy Tran; Kira Pavlik; Elin Rowen; Heather Gerrish; Annette Komlo; Richa Gupta; Hailey Wyatt; Matthew Ribeiro; Yuval Kluger; Geyu Zhou; Wei Wei; Veronica L Chiang; Harriet M Kluger
Journal:  Lancet Oncol       Date:  2020-04-03       Impact factor: 41.316

Review 2.  All About (NK Cell-Mediated) Death in Two Acts and an Unexpected Encore: Initiation, Execution and Activation of Adaptive Immunity.

Authors:  Ariel Ramírez-Labrada; Cecilia Pesini; Llipsy Santiago; Sandra Hidalgo; Adanays Calvo-Pérez; Carmen Oñate; Alejandro Andrés-Tovar; Marcela Garzón-Tituaña; Iratxe Uranga-Murillo; Maykel A Arias; Eva M Galvez; Julián Pardo
Journal:  Front Immunol       Date:  2022-05-16       Impact factor: 8.786

Review 3.  The impact of aging on innate and adaptive immunity in the human female genital tract.

Authors:  Marta Rodriguez-Garcia; Mickey V Patel; Zheng Shen; Charles R Wira
Journal:  Aging Cell       Date:  2021-05-05       Impact factor: 9.304

4.  Differential Cytotoxic Function of Resident and Non-resident CD8+ T Cells in the Human Female Reproductive Tract Before and After Menopause.

Authors:  Marta Rodriguez-Garcia; Zheng Shen; Jared M Fortier; Charles R Wira
Journal:  Front Immunol       Date:  2020-06-04       Impact factor: 7.561

5.  Lung metastases share common immune features regardless of primary tumor origin.

Authors:  Sandra García-Mulero; M Henar Alonso; Julián Pardo; Cristina Santos; Xavier Sanjuan; Ramón Salazar; Victor Moreno; Josep María Piulats; Rebeca Sanz-Pamplona
Journal:  J Immunother Cancer       Date:  2020-06       Impact factor: 13.751

6.  Extracellular NK histones promote immune cell anti-tumor activity by inducing cell clusters through binding to CD138 receptor.

Authors:  B Martín-Antonio; G Suñe; A Najjar; L Perez-Amill; A Antoñana-Vildosola; M Castella; S León; M Velasco-de Andrés; F Lozano; E Lozano; C Bueno; J M Estanyol; C Muñoz-Pinedo; S N Robinson; A Urbano-Ispizua
Journal:  J Immunother Cancer       Date:  2019-10-16       Impact factor: 13.751

7.  s-SHIP Promoter Expression Identifies Mouse Mammary Cancer Stem Cells.

Authors:  Lu Tian; Marie-José Truong; Chann Lagadec; Eric Adriaenssens; Emmanuel Bouchaert; Hélène Bauderlique-Le Roy; Martin Figeac; Xuefen Le Bourhis; Roland P Bourette
Journal:  Stem Cell Reports       Date:  2019-06-13       Impact factor: 7.765

Review 8.  Modulation of Inflammation by Extracellular Granzyme A.

Authors:  Kim R van Daalen; Josephine F Reijneveld; Niels Bovenschen
Journal:  Front Immunol       Date:  2020-05-19       Impact factor: 7.561

Review 9.  The Multifaceted Function of Granzymes in Sepsis: Some Facts and a Lot to Discover.

Authors:  Marcela Garzón-Tituaña; Maykel A Arias; José L Sierra-Monzón; Elena Morte-Romea; Llipsy Santiago; Ariel Ramirez-Labrada; Luis Martinez-Lostao; José R Paño-Pardo; Eva M Galvez; Julián Pardo
Journal:  Front Immunol       Date:  2020-06-17       Impact factor: 7.561

10.  Loss of BAP1 expression is associated with an immunosuppressive microenvironment in uveal melanoma, with implications for immunotherapy development.

Authors:  Carlos R Figueiredo; Helen Kalirai; Joseph J Sacco; Ricardo A Azevedo; Andrew Duckworth; Joseph R Slupsky; Judy M Coulson; Sarah E Coupland
Journal:  J Pathol       Date:  2020-04       Impact factor: 7.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.